Kidney Cancer Clinical Trial
A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
Summary
In spite of the overall success of treating Wilms tumor, certain patients still have poor clinical outcomes. The sub-optimal outcomes for patients with anaplastic histology and recurrent Wilms tumor warrant the identification of new therapeutic agents. The objective of this trial is to estimate the response rate to two cycles of intravenous topotecan in children with recurrent Wilms tumor of favorable histology that is refractory to standard curative therapy.
Full Description
Topotecan administered intravenously over 30 minutes daily for 5 consecutive days for 2 consecutive weeks, with a two-day rest given in between the five-day treatment blocks. The topotecan dose started at 1.8 mg/m2/dosage and adjusted to attain a target systemic exposure of 80 plus or minus 10 ng-hr/ml.each cycle consists of 28 days and subsequent cycles can be administered upon hematological recovery. Patients with a CR, PR, or SD, can continue to receive up to a total of six cycles. Patients with PD are removed from the study.
Secondary Objectives include:
To describe the anti-tumor activity of topotecan in children with recurrent Wilms tumor of anaplastic histology.
To assess the relation between CYP3A4/5 genotype and the pharmacokinetics and pharmacodynamics of topotecan.
To assess the relation between ABCG2 genotype and the pharmacokinetics and pharmacodynamics of topotecan.
Eligibility Criteria
Inclusion Criteria:
Favorable histology Wilms tumor that has recurred or progressed after primary treatment and at least one standard salvage treatment regimen OR anaplastic histology Wilms tumor that has recurred or progressed after primary treatment
Age< 21 years of age at the time of study entry
Adequate bone marrow function
Adequate liver function
Adequate renal function
Adequate performance status
Exclusion Criteria:
Subject is pregnant
Subject is lactating
Renal tumors other than Wilms tumors
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Atlanta Georgia, 30301, United States
Boston Massachusetts, 02115, United States
Memphis Tennessee, 38105, United States
Houston Texas, 77030, United States
Calgary Alberta, T2N 4, Canada
Calgary Alberta, T2W 3, Canada
Toronto Ontario, M5G 1, Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.